Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Spangemacher

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Autism and Developmental Disorders|July 31, 2021
Brief Report: Specificity of Interpersonal Synchrony Deficits to Autism Spectrum Disorder and Its Potential for Digitally Assisted DiagnosticsJana Christina Koehler, Alexandra Livia Georgescu, Johanna Weiske, et al.
Neuroscience Applied|July 14, 2025
Neurovascular coupling of striatal dopamine D<sub>2/3</sub> receptor availability and perfusion using simultaneous PET/MR in humansChristian N Schmitz, Xenia M Hart, Moritz Spangemacher, et al.
Frontiers in Psychiatry|July 24, 2024
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational studyBruno Pedraz-Petrozzi, Moritz Spangemacher, Anton Deicher, et al.
Brain, Behavior, and Immunity|July 5, 2026
Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depressionBruno Pedraz-Petrozzi, Marta Marszalek-Grabska, Emilia Fornal, et al.
JAMA Psychiatry|March 18, 2026
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical TrialLea J Mertens, Michael Koslowski, Felix Betzler, et al.
Psychotherapy and Psychosomatics|May 27, 2026
Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialLea J Mertens, Felix Betzler, Manuela Brand, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Autism and Developmental Disorders|July 31, 2021
Brief Report: Specificity of Interpersonal Synchrony Deficits to Autism Spectrum Disorder and Its Potential for Digitally Assisted DiagnosticsJana Christina Koehler, Alexandra Livia Georgescu, Johanna Weiske, et al.
Neuroscience Applied|July 14, 2025
Neurovascular coupling of striatal dopamine D<sub>2/3</sub> receptor availability and perfusion using simultaneous PET/MR in humansChristian N Schmitz, Xenia M Hart, Moritz Spangemacher, et al.
Frontiers in Psychiatry|July 24, 2024
Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational studyBruno Pedraz-Petrozzi, Moritz Spangemacher, Anton Deicher, et al.
Brain, Behavior, and Immunity|July 5, 2026
Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depressionBruno Pedraz-Petrozzi, Marta Marszalek-Grabska, Emilia Fornal, et al.
JAMA Psychiatry|March 18, 2026
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical TrialLea J Mertens, Michael Koslowski, Felix Betzler, et al.
Psychotherapy and Psychosomatics|May 27, 2026
Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialLea J Mertens, Felix Betzler, Manuela Brand, et al.
Pageof 2